Lupin Ltd (LUPIN)
₹2,011.00
Mkt cap
₹91,962 Cr
P/E ratio
15.40
P/B
4.10
Div yield
0.90%
ROE
28.70%
ROCE
29.90%
EPS (TTM)
₹130.58
Book value
₹491
52W range
1,893–2,530
Sector
Healthcare
Price history
Previous close
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
NSE LUPINBSE 500257
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−20.50% from high₹2,011
₹1,893+6.24% from low₹2,530
Current
₹2,011.00
Prev close
₹1,989.90
Day
+1.06%
Price performance
1D
+1.06%
1W
+4.26%
1M
−2.00%
3M
−16.94%
6M
−13.00%
1Y
+3.67%
YTD
−4.48%
Financials
Revenue, profit & margin
P/E ratio
15.4×
LUPIN is 55% below the sector median of 34.4×
LUPIN15.4×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 | |
| Expenses | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 | |
| Operating Profit | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 | |
| OPM % | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% | |
| Other Income | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 | |
| Interest | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 | |
| Depreciation | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 | |
| Profit before tax | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 | |
| Tax % | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% | |
| Net Profit | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 | |
| EPS in Rs | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.66% · closed higher next day 31 of last 61
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23 | 7 Feb '24◦ | 7 May '24 | 6 Aug '24◦ | 7 Nov '24◦ | 12 Feb '25 | 14 May '25 | 5 Aug '25◦ | 6 Nov '25◦ | 12 Feb '26◦ | 7 May '26◦ | 6 Aug '26◦ |
| Earnings day | −0.54% | +0.76% | −4.11% | +4.38% | −0.33% | −2.05% | +0.07% | −0.68% | +0.83% | −0.53% | −3.28% | −0.90% |
| +1 day | −2.56% | +1.74% | −3.78% | +7.33% | −1.26% | −0.60% | −0.14% | +4.27% | +1.77% | +0.47% | −8.30% | −3.56% |
| +5 days | −1.22% | +0.68% | −2.53% | +8.54% | −3.59% | −4.32% | −4.96% | +6.72% | +5.10% | +0.38% | −7.48% | −6.29% |
| +15 days | +4.08% | +1.68% | −4.54% | +14.81% | −1.41% | −2.37% | −3.68% | +1.63% | +6.48% | +4.16% | −8.02% | −8.95% |
| +30 days | +5.91% | +0.87% | −6.39% | +13.67% | +2.74% | −1.92% | −6.89% | +10.25% | +8.71% | +2.89% | −4.88% | −10.92% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 18 Per Share | 18.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
as of Sep 202646.84%Promoter
Promoters46.84%
FIIs23.28%0.86
DIIs23.78%0.87
Public6.08%
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Lupin | ₹2,011.00 | 15.44 | 91,962 | 0.90% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts86
TranscriptAug 2026PPTAug 2026RECAug 2026PPTAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024
Credit ratings6
Announcements5
General Updates 24 Oct - US FDA inspection at Goa facility ended October 23, 2026 with one Form-483 observation.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 23 Oct - Intimation of allotment of 3,033 equity shares under ESOP.Announcement under Regulation 30 (LODR)-Press Release / Media Release 23 Oct - Lupin appoints Brian Savage as President, Chief Legal Officer, effective October 23, 2026.Announcement under Regulation 30 (LODR)-Change in Management 22 Oct - Lupin appoints Brian Savage as President and Chief Legal Officer effective October 22, 2026.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 19 Oct - Intimation regarding Grant of 40,157 Stock Options under Lupin Employees Stock Option Scheme 2025.